N/A N=32 Assessment of Colonic Epithelial Integrity With Mucosal Impedance
Inflammatory Bowel Diseases
Primary: Mucosal Impedance Values — 1139; 849; 891; 783 ohms
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=204 Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers
Upper Gastrointestinal Mucosal Damage
Primary: Incidence of Subjects With Gastroduodenal Erosions and Ulcers. — 72; 54; 19; 36 participants
Phase 4 N=28 Gastrointestinal Safety Evaluation of Two Over the Counter Analgesics
Gastrointestinal Mucosal Damage
Primary: Gastromucosal Damage (GMD) Score of Paracetamol Tablet vs Ibuprofen Capsule — 0.33; 1.48 Scores on a scale — p=<0.0001
N/A N=16 Diet Induced Intestinal Mucosal Adaptation
Healthy Conditions
Primary: Mucosal Surface Enlargement — 10.2; 9.9 percentage of muscular mucosae — p=<0.05
Phase 3 N=111 Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate
Autoimmune Disease
Primary: Changes in GI Symptom Severity After Conversion From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) — 2.28; 2.02; -0.28 Scores on a scale
Phase 4 N=23 Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®
Gastrointestinal Lesions · Signs and Symptoms, Digestive
Primary: GI Mucosal Lesions Change and Clinical Symptoms Using The Gastrointestinal Symptom Rating Scale (GSRS) Score — 2.99; 2.19 GSRS score — p=0.05
Phase 2 N=247 Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
Gastroduodenal Ulceration
Primary: Incidence of Gastroduodenal Ulcers — 28; 34 participants
N/A N=15 Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)
Crohn Disease
Primary: Change From Baseline in the Crohn's Disease Endoscopic Index of Severity (CDEIS) Blinded Score at Week 6 — -4.8 Score on a scale
N/A N=54 Gulf War Digestive Health Study
Irritable Bowel Syndrome · Small Intestinal Bacterial Overgrowth
Primary: Global Improvement Scale — 4.3; 4.3 units on a scale — p=0.26
Phase 2 N=77 Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults
Gastroduodenal Ulcerations · Erosion
Primary: Degree of GI Injury at Day 15 — 23; 20; 11; 13 participants
Phase 1 N=24 Gastrointestinal Integrity After Naproxen + Rebamipide Versus Naproxen + Placebo
Gastrointestinal Lesions
Primary: Endoscopic Score - Cryer Score — 4; 4 Cryer score
Phase 3 N=34 Measurement of Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients
Liver Transplantation
Primary: Changes in Gastrointestinal Symptom Severity and Health Related Quality of Life — 2.88; 2.10 Scores on a Scale
Phase 4 N=14 Effects of Gastric Acid on Colonic Microbiome
Clostridium Difficile
Primary: Shannon Diversity Index Measuring Change in Microbiome Diversity — 0.18; 0.14 Shannon index — p=0.71
N/A N=80 The Second-Generation MCCG for Upper Gastrointestinal Tract.
Capsule Endoscopy
Primary: Circumferential Visualization of the Z-line — 0; 5; 5; 7 Participants
Phase 3 N=31 Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants
Pancreas Transplantation · Kidney Transplantation
Primary: Changes in Gastrointestinal Symptom Severity and/or Health-related Quality of Life After Conversion From MMF to Enteric Coated Mycophenolate Sodium — -0.46 Change in…
Phase 3 N=89 Mucosal Healing Study in Crohn's Disease (CD)
Crohn's Disease
Primary: Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments — -6.47 score on a scale
N/A N=40 Glycocalyx Damage in Critically Ill Patients
Critical Illness
Primary: Perfused Boundary Region (PBR) in One Week — 1.95; 1.97; 2.02 micrometer
N/A N=54 Efficacy and Safety of Hizikia Fusiformis Extract in Subjects Showing Erosive Gastritis
Erosive Gastritis
Primary: Changes in Erosions — 4.36; 3.38; 2.32; 2.43 erosions
Phase 3 N=135 Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon
Crohn's Disease
Primary: Number of Subjects Without Mucosal Ulceration at Week 12 — 8; 17 Subjects — p=0.056
N/A N=41 Damage Control for Duodenal and Combined Duodenal-Pancreatic Injuries
Injury of Duodenum · Pancreatic Injury
Primary: Duodenal-related Complications — 13; 11; 8; 19 percentage of subjects
Phase 2 N=18 Evaluation of Blood as a Submucosal Cushion During Endoscopic Polypectomy and Mucosal Resection
Large Polyps in the Gastrointestinal Tract
Primary: Duration of the Submucosal Cushion
Phase 3 N=311 Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients
Stress Ulcer Prophylaxis
Primary: The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation Phase — 2.7; 4.6 % of participants — p=0.393
N/A N=48 Evaluation of the Gastrointestinal Manifestation of Fabry's Disease
Fabry's Disease
Primary: Gastric Emptying Transit Time Measured Via SmartPill Study — 2.9; 2.8 Hours
Phase 4 N=10 Effect of Antibiotics on Enteric Neurons and Glia
Antibiotic Enterocolitis
Primary: Change in Mean Number of Colonic Submucosal Neurons/mm^2 in the Colon After Antibiotic Treatment — 0 neuronal cells/mm^2
Phase 3 N=91 GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
Head and Neck Cancer · Mucositis Oral · Radiation Toxicity
Primary: Comparison of Number of Participants With Grade 1 or 2 Oral Mucositis (GM-CSF and SS Groups Only) — 28; 46 participants — p=0.09
N/A N=22 Aging and Gastrointestinal Barrier Function
Aging · Hyperthermia
Primary: Log Lactulose/Rhamnose Following Control Trial — 0.97; 0.79 Ratio
N/A N=126 Acetic Acid Chromoendoscopy to Judge Gastric Intestinal Metaplasia
Stomach Neoplasms · Metaplasia
Primary: Percent Agreement Between Acetic Acid Chromoendoscopy and Endoscopic Biopsy — 78.5; 94.4; 89.2; 67.1 percentage of lesions
Phase 2 N=40 Cox-2 Inhibition in Radiation-induced Oral Mucositis
Oral Mucositis
Primary: Clinical Oral Mucosal Injury Score at Cumulative Radiation Dose of 5000 cGy — 1.42; 1.36 units on a scale
Phase 4 N=301 Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer
Stomach Ulcer
Primary: Gastric Ulcer Healing Rate (Number of Subjects Whose Gastric Ulcer Was Healed/Number of Subjects Evaluated x 100) at Week 8 — 70.13; 60.54 percentage of participants
N/A N=40 Closure of Mucosal and Submucosal Defects in the Gastrointestinal Tract Using the Novel X-Tack Endoscopic Suturing Device
Polyp of Colon · Fistula
Primary: Time to Closure — 23.3; 18.4 minutes